DE3887156T2 - Verwendung von handelsüblichem lezithin als hautpenetrationsförderer. - Google Patents

Verwendung von handelsüblichem lezithin als hautpenetrationsförderer.

Info

Publication number
DE3887156T2
DE3887156T2 DE88903109T DE3887156T DE3887156T2 DE 3887156 T2 DE3887156 T2 DE 3887156T2 DE 88903109 T DE88903109 T DE 88903109T DE 3887156 T DE3887156 T DE 3887156T DE 3887156 T2 DE3887156 T2 DE 3887156T2
Authority
DE
Germany
Prior art keywords
skin penetration
commercial lecithin
conveyor
penetration conveyor
lecithin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE88903109T
Other languages
English (en)
Other versions
DE3887156T3 (de
DE3887156D1 (de
Inventor
Mahdi Fawzi
Uma Iyer
Majid Mahjour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21895652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3887156(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of DE3887156D1 publication Critical patent/DE3887156D1/de
Publication of DE3887156T2 publication Critical patent/DE3887156T2/de
Publication of DE3887156T3 publication Critical patent/DE3887156T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE3887156T 1987-04-13 1988-03-18 Verwendung von handelsüblichem lezithin als hautpenetrationsförderer. Expired - Fee Related DE3887156T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/037,671 US4783450A (en) 1987-04-13 1987-04-13 Use of commercial lecithin as skin penetration enhancer
PCT/US1988/000886 WO1988007871A1 (en) 1987-04-13 1988-03-18 Use of commercial lecithin as skin penetration enhancer

Publications (3)

Publication Number Publication Date
DE3887156D1 DE3887156D1 (de) 1994-02-24
DE3887156T2 true DE3887156T2 (de) 1994-04-28
DE3887156T3 DE3887156T3 (de) 1998-04-16

Family

ID=21895652

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3887156T Expired - Fee Related DE3887156T3 (de) 1987-04-13 1988-03-18 Verwendung von handelsüblichem lezithin als hautpenetrationsförderer.

Country Status (5)

Country Link
US (1) US4783450A (de)
EP (1) EP0382716B2 (de)
JP (1) JP2714413B2 (de)
DE (1) DE3887156T3 (de)
WO (1) WO1988007871A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981681A (en) * 1988-08-26 1991-01-01 Vittorio Tosti Lotion mixture and method of treating psoriasis
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5498607A (en) * 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
WO1993011767A1 (en) * 1991-12-18 1993-06-24 Warner-Lambert Company Transdermal delivery of (e)-1,2,5,6-tetrahydro-1-methyl-3-pyridine-carboxaldehyde-o-methyloxine hcl and related compounds in the treatment of cognitive disorders and for analgesia
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
ATE138561T1 (de) * 1992-02-12 1996-06-15 Janssen Cilag S P A Liposomale itraconazol formulierungen
DK0625898T3 (da) * 1992-02-12 1996-06-03 Janssen Cilag S P A Liposom-piroxicamformuleringer
EP0625898B1 (de) * 1992-02-12 1996-05-15 JANSSEN-CILAG S.p.A. Liposomale piroxycam formulierung
TW224048B (de) * 1992-03-30 1994-05-21 Hoechst Roussel Pharma
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
DE69420419T2 (de) * 1993-09-29 1999-12-23 Alza Corp Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
US5945409A (en) 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
WO1997002041A1 (en) 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
SE9601528D0 (sv) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5709878A (en) * 1996-08-02 1998-01-20 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
GB2331924A (en) * 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6011022A (en) * 1998-03-03 2000-01-04 El Khoury; George F. Topical application of muscarinic analgesic drugs such as neostigmine
EE200100342A (xx) 1998-12-23 2002-10-15 Idea Ag Parendatud ravimvorm in vivo mitteinvasiivseks paikseks rakendamiseks
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
DE10024413A1 (de) * 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US8980290B2 (en) * 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
DE60143360D1 (de) * 2000-08-03 2010-12-09 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
AU2002250071B2 (en) 2001-02-13 2008-02-14 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
US6803420B2 (en) 2001-05-01 2004-10-12 Corium International Two-phase, water-absorbent bioadhesive composition
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
EP1539069A4 (de) * 2002-05-31 2007-11-14 Univ Mississippi Transmukosale abgabe von cannabinoiden
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
EP1670433B1 (de) 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
JP5594925B2 (ja) 2004-01-30 2014-09-24 コリウム インターナショナル， インコーポレイテッド 活性物質の送達のための急速に溶解するフィルム
US20050191338A1 (en) * 2004-01-30 2005-09-01 Lifeng Kang Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
JP2007538010A (ja) 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
JP2008519784A (ja) * 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
EP1852130B1 (de) * 2005-02-25 2012-06-20 Hisamitsu Pharmaceutical Co. Inc. Medizin zur äusseren anwendung mit entzündungshemmendem mittel und sojalecithin
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
KR101522747B1 (ko) 2007-08-06 2015-05-26 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
US20110052738A1 (en) * 2008-01-17 2011-03-03 Gary Dean Bennett Topical pain formulation
WO2009110205A1 (ja) 2008-03-04 2009-09-11 ナガセケムテックス株式会社 ヒアルロン酸増量剤
US20090258841A1 (en) 2008-04-01 2009-10-15 Michael Patrick Murphy Compositions and methods for skin care
US20090258070A1 (en) 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
HUE039013T4 (hu) 2008-05-21 2019-08-28 Ferring Bv Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
AU2009335740B2 (en) 2008-12-17 2016-04-21 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
EP3695835A1 (de) 2009-02-03 2020-08-19 Microbion Corporation Bismutthiole als antiseptika für epithelgewebe, akute und chronische wunden, bakterielle biofilme und andere anwendungsgebiete
WO2011133948A2 (en) 2010-04-22 2011-10-27 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
ES2702490T3 (es) 2011-05-03 2019-03-01 Dupont Nutrition Biosci Aps Bacterias probióticas para el tratamiento tópico de trastornos de la piel
US20130005708A1 (en) 2011-06-29 2013-01-03 Lalwani Dinusha N Histamine antagonist treatment of inflammatory skin disorders
SG11201501850VA (en) 2012-09-21 2015-04-29 Intensity Therapeutics Inc Method of treating cancer
EP2968469A4 (de) 2013-03-15 2016-08-31 Longevity Biotech Inc Peptide mit nichtnatürlichen aminosäuren und verfahren zur herstellung und verwendung davon
AU2014293141A1 (en) 2013-07-23 2016-02-18 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
JP2016525147A (ja) 2013-07-23 2016-08-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ５−α還元酵素阻害剤と組み合わせたデスモプレシンを含む方法及び組成物
ES2895600T3 (es) 2013-11-15 2022-02-22 Oncoceutics Inc 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso de la misma en terapia de combinación
US20150182451A1 (en) * 2013-12-27 2015-07-02 The Dial Corporation Cleansing composition for hormone deposition
AU2015301432B2 (en) 2014-08-15 2019-11-21 The Johns Hopkins University Composite material for tissue restoration
EP3220942B1 (de) 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Zusammensetzungen mit niedriger dose desmopressin in kombination mit einem alpha-adrenorezeptor-antagonisten
SI3250208T1 (sl) 2015-01-30 2021-01-29 Oncoceutics, Inc. 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo (1,2-A)pirido(3,4-E)pirimidin-5-(4H)-on in njegove soli ter njihova uporaba v terapiji
CN107613961B (zh) * 2015-05-19 2021-07-13 美德阿利克斯株式会社 经皮吸收型液体制剂
EP4091639A1 (de) 2015-08-17 2022-11-23 The Johns Hopkins University In-situ-herstellung von verbundmaterial zur gewebewiederherstellung
BR112018015590A2 (pt) 2016-01-29 2019-10-01 Oncoceutics Inc modulação de receptor acoplado à proteína g (gpcr) por imipridonas
CA3048334A1 (en) 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
JP2021522938A (ja) 2018-05-09 2021-09-02 ザ ジョンズ ホプキンス ユニバーシティ 細胞及び組織の送達のためのナノファイバー−ハイドロゲル複合体
AU2019265839A1 (en) 2018-05-09 2020-12-03 The Johns Hopkins University Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration
EP3863622A1 (de) 2018-10-09 2021-08-18 University Of Rochester Behandlung von vulvovaginalen störungen
EP3914227A1 (de) 2019-01-25 2021-12-01 Nogra Pharma Limited Zusammensetzungen zur verwendung in der vorbeugung von akne
KR20230128451A (ko) * 2020-11-06 2023-09-05 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비노이드 캡슐화 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2001334B (en) * 1977-07-19 1982-03-03 Fisons Ltd Pressurised aerosol formulation
FR2478485A1 (fr) * 1980-03-24 1981-09-25 Oreal Compositions cosmetiques ou pharmaceutiques sous forme d'emulsions stables du type huile-dans-l'eau
US4699776A (en) * 1985-06-28 1987-10-13 R. P. Scherer Corporation Suppositories containing analgesics, antipyretics or anti-inflammatory agents
JPS62123132A (ja) * 1985-11-21 1987-06-04 Michio Nakanishi 気管支喘息治療用組成物

Also Published As

Publication number Publication date
JP2714413B2 (ja) 1998-02-16
EP0382716B2 (de) 1998-01-28
US4783450A (en) 1988-11-08
DE3887156T3 (de) 1998-04-16
EP0382716A1 (de) 1990-08-22
EP0382716B1 (de) 1994-01-12
JPH02502994A (ja) 1990-09-20
DE3887156D1 (de) 1994-02-24
WO1988007871A1 (en) 1988-10-20

Similar Documents

Publication Publication Date Title
DE3887156D1 (de) Verwendung von handelsüblichem lezithin als hautpenetrationsförderer.
DE3670448D1 (de) Herzschrittmacher.
DE3856192T2 (de) Ratenadaptierender Herzschrittmacher
DE3882250D1 (de) Herzdefibrillator.
DE3876469T2 (de) Hautaequivalent.
ATA143089A (de) Herzschrittmacher
NL191672C (nl) Implanteerbare defibrillator.
DE3789036D1 (de) Herzschrittmacher.
DE3883651D1 (de) Herzschlagabhängiger Schrittmacher.
DE3884692T2 (de) Defibrillator.
DE3668557D1 (de) Herzschrittmacher.
DE3852893D1 (de) Herzschrittmacher.
DE3670208D1 (de) Herzschrittmacher.
ATE112172T1 (de) Targetformer von antitumor-methyltrithioagenzien.
FR2559391B3 (fr) Stimulateur cardiaque implantable
DE3581476D1 (de) Kopfoese zur befestigung von druckknoepfen.
FR2559671B3 (fr) Stimulateur cardiaque implantable
ATE99960T1 (de) Verwendung von handelsueblichem lezithin als hautpenetrationsfoerderer.
DE3871977T2 (de) Herzschrittmacher.
DE3779211D1 (de) Verwendung von dihydrobenzopyranderivaten.
AT388763B (de) Herzstueck
FR2558732B3 (fr) Stimulateur cardiaque implantable
DE59003369D1 (de) Verwendung von Triacetin in Gleitmitteln.
NO880613D0 (no) Blodprodukter.
KR880021166U (ko) 1회용 슬리퍼

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8339 Ceased/non-payment of the annual fee